Interleukin 10 (IL10) antibody

Details for Product No. ABIN967464
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

 
Antigen
Synonyms CSIF, GVHDS, IL-10, IL10A, TGIF, Il-10, IL10X
Reactivity
Human
(227), (143), (52), (27), (14), (14), (14), (13), (4), (2), (2), (2), (1)
Host
Rat
(148), (131), (94), (4), (4), (3), (1)
Clonality (Clone)
Monoclonal ()
Conjugate
Un-conjugated
(64), (11), (10), (5), (4), (4), (3), (2), (2), (2), (2), (2), (2), (2), (2), (1), (1), (1)
Application
Flow Cytometry (FACS), ELISA (Capture), Western Blotting (WB)
(255), (227), (94), (45), (39), (37), (33), (27), (26), (19), (17), (17), (12), (8), (8), (7), (7), (6), (4), (3), (2), (2), (2), (2), (1), (1)
Pubmed 8 references available
Catalog no. ABIN967464
Quantity 0.1 mg
Price
Contact our Customer Service for availability and price in your country.
Options
Shipping to United States (Change)
Add to Basket

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen COS-expressed Recombinant Human IL-10
Clone JES3-9D7
Isotype IgG1
Cross-Reactivity Virus
Characteristics 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
Purification Purified from tissue culture supernatant or ascites by affinity chromatography.
Purity Purified
Alternative Name IL-10
Background The JES3-9D7 antibody reacts with human IL-10 and viral IL-10. The immunogen used to generate the JES3-9D7 hybridoma was recombinant human IL-10 expressed in COS cells. This antibody is routinely tested by intracellular staining.
Research Area Cytokines, Immunology, Virology, Inflammation, Cancer
Application Notes Blocking Control for Intracellular Staining:
The purified JES3-9D7 antibody can be used as a blocking control to demonstrate specificity of IL-10 staining by PE-JES3-9D7 antibody. To perform this control, the fixed/permeabilized cells (~ 1 million) can be incubated with 1-10 µg of unlabeled JES3-9D7 antibody (ABIN967464) for 20 minutes at 4°C, prior to staining with PE-JES3-9D7 antibody (e.g., 0.1 - 0.5 µg mAb/1 million cells). The intracellular cytokine staining technique and use of blocking controls are described in detail by C. Prussin and D. Metcalfe.

Neutralization:
The NA/LE format of the JES3-9D7 antibody is useful for neutralization of human or viral IL-10 bioactivity. A suitable NA/LE™ rat IgG1 isotype control to match the NA/LE™ JES3-9D7 antibody is the R3-34 antibody.

3. WB: The JES3-9D7 antibody (e.g., ABIN967464) has been reported to be useful for Western blotting. Please note that this application is not routinely tested.
Restrictions For Research Use only
Format Liquid
Concentration 0.5 mg/ml
Buffer Aqueous buffered solution.
Preservative Sodium azide
Storage 4 °C
Supplier Images
anti-Interleukin 10 (IL10) antibody Expression of IL-10 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 24 hours with LPS (1.0 µg/ml final concentration) in the presence of GolgiStop™ (2 µM final concentration). The PBMC were harvested, stained with FITC-mouse anti-human CD14 antibody (FITC-M5E2), fixed, permeabilized, and subsequently stained with 0.25 µg of PE-rat anti-human IL-10 antibody (PE-JES3-9D7) following Pharmingen's staining protocol (first panel). The data reflect gating on monocytes, based on forward and side light scatter. To demonstrate specificity of staining, the binding of PE-JES3-9D7 was blocked by the preincubation of the conjugated antibody with recombinant human IL-10 (0.5 µg, middle panel), and by preincubation of the fixed/permeabilized cells with the unlabeled JES3-9D7 antibody (5.0 µg, ABIN967464, second panel) prior to staining with the PE-JES3-9D7 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence control, and verified with the recombinant cytokine blocking (middle panel) and unlabeled antibody (second panel) blocking specificity controls.
anti-Interleukin 10 (IL10) antibody (2) Recombinant cytokine blocking
anti-Interleukin 10 (IL10) antibody (3) Unlabeled antibody
Product cited in: Abrams: "Immunoenzymetric assay of mouse and human cytokines using NIP-labeled anti-cytokine antibodies." in: Current protocols in immunology / edited by John E. Coligan ... [et al.], Vol. Chapter 6, pp. Unit 6.20, 2008 (PubMed).

General Yssel, De Waal Malefyt, Roncarolo et al.: "IL-10 is produced by subsets of human CD4+ T cell clones and peripheral blood T cells." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 149, Issue 7, pp. 2378-84, 1992 (PubMed).

Abrams, Roncarolo, Yssel et al.: "Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples." in: Immunological reviews, Vol. 127, Issue 9-10, pp. 5-24, 1992 (PubMed).

Gotlieb, Abrams, Watson et al.: "Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers." in: Cytokine, Vol. 4, Issue 5, pp. 385-90, 1992 (PubMed).

Just, Abrams, Louie et al.: "Influence of host genotype on progression to acquired immunodeficiency syndrome among children infected with human immunodeficiency virus type 1." in: The Journal of pediatrics, Vol. 127, Issue 4, pp. 544-9, 1995 (PubMed).

Kesslak, Yuan, Neeper et al.: "Vulnerability of the hippocampus to kainate excitotoxicity in the aged, mature and young adult rat." in: Neuroscience letters, Vol. 188, Issue 2, pp. 117-20, 1995 (PubMed).

Burdin, Péronne, Banchereau et al.: "Epstein-Barr virus transformation induces B lymphocytes to produce human interleukin 10." in: The Journal of experimental medicine, Vol. 177, Issue 2, pp. 295-304, 1993 (PubMed).

Prussin, Metcalfe: "Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies." in: Journal of immunological methods, Vol. 188, Issue 1, pp. 117-28, 1996 (PubMed).

Hosts (148), (131), (94), (4), (4), (3), (1)
Reactivities (227), (143), (52), (27), (14), (14), (14), (13), (4), (2), (2), (2), (1)
Applications (255), (227), (94), (45), (39), (37), (33), (27), (26), (19), (17), (17), (12), (8), (8), (7), (7), (6), (4), (3), (2), (2), (2), (2), (1), (1)
Conjugates (64), (11), (10), (5), (4), (4), (3), (2), (2), (2), (2), (2), (2), (2), (2), (1), (1), (1)
Epitopes (10), (4), (3), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1)
back to top